Roche and partner Alnylam said on Tuesday their experimental drug against high blood pressure was shown to work when used in combination with the standard of care in a phase 2 trial.

Venclexta trial deaths force AbbVie, Roche to stop recruiting myeloma patients The treatment achieved blockbuster status in 2020 and generated sales of $2.6 billion last year, an increase of 13% ...

Por Emma Thomasson BASILEA, 26 jul (Reuters) – La farmac (c)utica suiza Roche Holding dijo el jueves que asumi ‘ cargos por reestructuraci ‘n de 1.700 millones de d ‘lares, … ...

Roche, ViiV Healthcare and Horizon Therapeutics topped the list while Pfizer slipped from the highest tier, according to patient groups and compiled in a report by U.K. consultancy PatientView. The ...

Already facing the launch of U.S. biosimilar competitors to two of its oncology blockbusters, Roche is facing a tough road ahead. | With U.S. biosimilar competition targeting two of its top ...